National Academies Press: OpenBook

Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary (2013)

Chapter: Appendix C: Registered Workshop Attendees

Get This Book
Visit NAP.edu/10766 to get more information about this book, to buy it in print, or to download it as a free PDF.
« Previous: Appendix B: Participant Biographies
Page 149 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel

Appendix C

Registered Workshop Attendees

Olusoji Adeyi

Sector Manager

World Bank

Vincent Ahonkhai

Senior Regulatory Affairs Officer

Gates Foundation

Sarah Alphs

Research Associate

The William Davidson Institute at the University of Michigan

Rifat Atun

Professor of International Health Management

Imperial College London

Jim Barrington

Global Progam Director

Novartis

Amy Bloom

Acting Chief, Infectious Diseases Division

USAID

Barry Bloom

Harvard University Distinguished Service Professor and Joan L. and Julius H. Jacobson Professor of Public Health

Harvard School of Public Health

Anthony Boni

Pharmaceutical Specialist

USAID

Gail Cassell

Visiting Professor

Harvard Medical School

Peter Cegielski

Team Leader for Drug-Resistant TB

U.S. Centers for Disease Control and Prevention

Page 150 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel

Rajni Chandrasekhar

Consultant

FSG Social Impact Consultants

Gordon Comstock

Director, Global Supply Chain

Partnership for Supply Chain Management

Henk den Besten

Senior Supply Chain Advisor

Partnership for Supply Chain Management

Lucica Ditiu

Executive Secretary

World Health Organization, Stop TB Partnership

Suzanne Essama-Bibi

TB Technical Advisor

FHI 360

David Ferreira

Managing Director for Innovative Finance

GAVI Alliance

Gary Filerman

President

Atlas Health Foundation

Hamish Fraser

Assistant Professor of Medicine

Director of Informatics and Telemedicine

Partners In Health

Harvard Medical School

Anne Goldfeld

Professor of Medicine

Global Health Committee

Harvard Medical School

Jose Gomez-Marquez

Director

MIT Little Devices Lab

Andrew Gray

Senior Lecturer, Pharmaceutical Sciences

School of Health Sciences

University of KwaZulu-Natal

Carol Hamilton

Senior Scientist

FHI 360

Debra Hanna

Associate Director, CPTR

Critical Path Institute

Lisa Hedman

Project Manager

World Health Organization

Myriam Henkens

International Medical Coordinator

Médecins Sans Frontières

Brad Herbert

Managing Director

Brad Herbert Associates

Julia Hipps

Senior Director

Eli Lilly and Company

Maria Insua

Senior Technical Advisor

University Research Co., LLC

Douglas Keene

Vice President

Center for Pharmaceutical Management

Management Sciences for Health

Page 151 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel

Joël Keravec

Brazil Country Program Director

Management Sciences for Health

Salmaan Keshavjee

Director, Program in Infectious Disease and Social Change

Harvard Medical School

Michael Kimerling

Senior Program Officer, Tuberculosis Global Health Program

Bill & Melinda Gates Foundation

Jenna Kohnke

Program Manager

American Cancer Society

Paul Lalvani

Director and Dean

Empower School of Health

Patrick Lukulay

Vice President Global Health Impact Programs

USP

Robert Matiru

TB Portfolio Manager

UNITAID

World Health Organization

Montserrat Meiro-Lorenzo

Senior Public Health Specialist

World Bank

Thomas Moore

World Health Organization, Stop TB Partnership

Sana Mostaghim

MDR TB Drug Access Project Manager

Clinton Health Access Initiative

Betsy Myers

Program Director for Medical Research

Doris Duke Charitable Foundation

Norbert Ndjeka

MDR TB Director

Department of Health, South Africa

Meg O’Brien

Director, Global Access to Pain Relief Initiative

American Cancer Society

Christophe Perrin

QA Pharmacist International Union Against

Tuberculosis and Lung Disease

Claire Queresi

Senior Program Officer

Results for Development Institute (R4D)

Iain Richardson

Senior Director, Global Supply Chain and Logistics

Eli Lilly and Company

David Ripin

Executive Vice President of Access Programs and Chief Scientific Officer

Clinton Health Access Initiative

Page 152 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel

Owen Robinson

Program Manager

Partners In Health

Paul Ryu

Regional Manager of Western Europe

Dong-A Pharmaceutical Co., Ltd.

Nina Schwalbe

Managing Director, Policy and Performance

GAVI Alliance

Robert Sebbag

Vice President, Access to Medicines

Sanofi

Andreas Seiter

Senior Health Specialist

World Bank

Pooja Shaw

Program Officer

Results for Development Institute (R4D)

Tracy Sims

Vice President

Eli Lilly & Co. Foundation

Robert Stanley

Manager

Partnership for Supply Chain Management

Trish Stroman

Principal

The Boston Consulting Group

Jami Taylor

Senior Director, Global Access Policy

Janssen, The Pharmaceutical Companies of Johnson & Johnson

Cheri Vincent

TB Team Leader

USAID

Brenda Waning

Coordinator, Market Dynamics

UNITAID

World Health Organization

Prashant Yadav

Director, Healthcare Research Initiative

University of Michigan

Andre Zagorski

Principal Technical Advisor for TB, Center for Pharmaceutical

Management Management Sciences for Health

Page 149 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel
Page 149
Page 150 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel
Page 150
Page 151 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel
Page 151
Page 152 Cite
Suggested Citation:"Appendix C: Registered Workshop Attendees." Institute of Medicine. 2013. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13524.
×
Save
Cancel
Page 152
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary Get This Book
×
Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary
Buy Paperback | $45.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB)—a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin)—face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them.

This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review:

-To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks.

-The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain.

-What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR])

- The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration

-Identification of potential innovative solutions to the problem

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!